PADELIPORFIN: A Novel Treatment for Upper Tract Urothelial Cancer

What is Padeliporfin?

Padeliporfin, also known by its other name WST11, is a new drug being studied for the treatment of certain types of cancer1. It's currently undergoing clinical trials to evaluate its safety and effectiveness in treating Upper Tract Urothelial Cancer (UTUC), a type of cancer that affects the lining of the urinary system in the upper part of the body, specifically in the kidney and ureter.

How Does Padeliporfin Work?

Padeliporfin is used in a treatment called Vascular Targeted Photodynamic Therapy (VTP). This innovative approach combines the drug with light activation to target and destroy cancer cells. Here's how it works1:

1. The drug is administered intravenously (through a vein) at a dose of 3.66 mg/kg over 10 minutes.
2. A special optical light fiber is placed near the tumor using a medical instrument called a ureteroscope.
3. The target area is then illuminated with light for 10 minutes, activating the drug and destroying the cancer cells.

What Conditions Does Padeliporfin Treat?

Padeliporfin is being studied specifically for the treatment of Transitional Cell Cancer of Renal Pelvis and Ureter1. This is a type of cancer that develops in the cells lining the renal pelvis (part of the kidney) and the ureter (the tube connecting the kidney to the bladder). The current study focuses on patients with low-grade, non-invasive upper tract urothelial carcinoma, which means the cancer is in its early stages and hasn't spread deeply into the surrounding tissues.

The ENLIGHTED Study

The main clinical trial investigating Padeliporfin is called the ENLIGHTED study (ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer)1. This is a Phase 3 study, which means it's in an advanced stage of clinical research. The study is designed to evaluate how safe and effective Padeliporfin VTP is in treating low-grade UTUC.

Treatment Phases

The ENLIGHTED study consists of three main phases1:

1. Induction Treatment Phase: Patients receive 1-3 Padeliporfin VTP treatments, each 4 weeks apart. The goal is to achieve a Complete Response (CR), which means no visible tumor, negative urine tests for cancer cells, and no evidence of tumor on biopsy.
2. Maintenance Treatment Phase: If CR is achieved, patients enter this 12-month phase. They receive additional VTP treatments if there's evidence of tumor recurrence that meets certain criteria.
3. Long-Term Follow-up Phase: Patients who complete the maintenance phase are followed for up to an additional 48 months to monitor for any cancer recurrence or treatment-related side effects.

Expected Outcomes

The ENLIGHTED study aims to measure several important outcomes1:

• The number of patients who achieve complete absence of UTUC tumors after treatment
• How long patients remain cancer-free after treatment
• The effect of the treatment on overall kidney function
• Whether the treatment helps preserve the kidney, avoiding the need for its surgical removal
• How the treatment affects patients who have blockages in their ureters

Safety and Long-Term Follow-up

The study includes extensive follow-up to ensure the safety of the treatment1. Patients will be monitored for up to 5 years after treatment to check for any long-term effects, including:

• Continued absence of cancer
• Preservation of the kidney
• Overall kidney function
• Any adverse events or side effects related to the treatment

Additionally, the study will collect blood, tumor, and urine samples for genomic sequencing. This will help researchers understand how genetic factors might influence treatment response and cancer progression1.